Gait Examination in Patients With Hemophilia in Austria

Hemophilia Clinical Trial

— JOSEPHA  

Official title:

Joint-health Outcome Scoring: Exploration in Patients With Hemophilia in Austria (JOSEPHA Phase 1)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03541811
• Other study ID #: JOSEPHA Phase 1
• Status: Completed
• Start date: July 2, 2018
• Est. completion date: July 1, 2019

Study information

• Verified date: August 2019
• Source: FH Campus Wien, University of Applied Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hemophilia is an inherited disease caused by deficiency in varying degrees of clotting factors VIII and IX. Depending on the percentage of clotting factor in the blood the disease is categorized as "severe" (<1%, characterized by spontaneous bleedings), "moderate" (1-5%) and "mild" (>5%). If untreated, recurrent bleeding into the synovial joints often results in irreversible damage due to destruction of the cartilages and progressive joint impairment.

3d-gait analysis has been demonstrated as valid method to assess abnormal gait patterns and to monitor disease progression in patients with hemophilia (PWH). Furthermore, its outcomes facilitate the design of individually tailored therapeutic programs. In contrast to radiological examinations, 3d-gait analyses take place under weight-bearing conditions, which is a relevant issue in terms of weight-induced pain.

This study aims to explore the applicability of 3-d gait analysis as biomarker (gait deviation index) for functional impairments in PWH. Besides 3-d gait scores, secondary endpoints such as biomarkers reflecting cartilage damage and a laterality-ratio of leg muscle mass (in the case of one-sided target joints) will be tested for their ability to detect functional impairments in young adults with hemophilia.

Based on sample size calculation, 24 subjects aged 16-49 years, able to walk without aids or assistance will be included in each of the two groups: control (healthy, male), PWH (severe or moderate, treated prophylactically). Subjects suffering from functional impairments caused by other conditions than hemophilia, patients with bleedings within 30 days prior to the examination, PWH treated with immune-tolerance therapy and/or not successfully treated present or past high-titer factor VIII or FIX inhibitor will be excluded.

Subjects will pass through a set of examinations (medical history, clinical examination, 3d-gait analysis, anthropometrics, body composition analysis, venipuncture, and urine sampling) and carry an accelerometer device for seven consecutive days.

Confounder adjusted group differences will be assessed by ANCOVA with contrasts and Bonferroni correction. Correlations between the applied examination approaches will be assessed.

An evidence based health promotion program including follow-up examinations, physical activity promotion, and tailored physiotherapy are being envisaged as a follow-up project (JOSEPHA phase 2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: July 1, 2019
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 16 Years to 49 Years

Eligibility

Inclusion Criteria (test group):

• Provide signed and dated informed consent form (additionally from guardian for participants aged under 18 years)

• Willing to comply with all study procedures and be available for the duration of the study

• Diagnosed severe or moderate hemophilia A or B

• Age between 16 and 49 years

• Able to walk without aids or assistance

• Treated with prophylactic substitution, initiated until the age of 18 years

Inclusion Criteria (control group):

• Provide signed and dated informed consent form (additionally from guardian for participants aged under 18 years)

• Willing to comply with all study procedures and be available for the duration of the study

• Male

• Age between 16 and 49 years (no blood samples for participants aged under 18 years)

• Physiological and symmetric gait pattern without using aids or assistance

Exclusion Criteria:

• Subjects suffering from functional impairments caused by other conditions than hemophilia

• PWH with joint bleedings within 30 days prior to the examination (applies for test group only)

• PWH treated with immune-tolerance therapy and/or not successfully treated present or past high-titer factor VIII or FIX inhibitor (applies for test group only)

Related Conditions & MeSH terms

• Hemophilia
• Hemophilia A

Intervention

Diagnostic Test:
• 3-d gait examination (level walking)
Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2. Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured.
• Anthropometrics and body composition assessment
Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
• Biomarkers
Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C. All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method).
• Clinical examination
Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
• Habitual physical activity tracking (accelerometer based)
Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.

Locations

Country	Name	City	State
Austria	FH Campus Wien - University of Applied Sciences	Vienna

Sponsors (3)

Lead Sponsor	Collaborator
FH Campus Wien, University of Applied Sciences	Medical University of Vienna, Shire

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gait Deviation Index (GDI)	Score expressing overall gait physiology; resulting from 3-d gait analysis [dimensionless]	May 2018 - Oct 2018 (anticipated)
Secondary	Kinematic gait parameters	Functional range of motion Hip, Knee, Ankle [°]	May 2018 - Oct 2018 (anticipated)
Secondary	Walking velocity	[m sec-1]	May 2018 - Oct 2018 (anticipated)
Secondary	Walking cadence	[steps min-1]	May 2018 - Oct 2018 (anticipated)
Secondary	Step length	[m]	May 2018 - Oct 2018 (anticipated)
Secondary	Stance phase duration	[% gait cycle]	May 2018 - Oct 2018 (anticipated)
Secondary	Swing phase duration	[% gait cycle]	May 2018 - Oct 2018 (anticipated)
Secondary	Body composition analysis	Bioelectrical impedance derived body fat rate [kg, %], fat-free mass [kg, %]	May 2018 - Oct 2018 (anticipated)
Secondary	Biomarkers measured from serum and urine	sCOMP, sC1,2C, sCS846, uCTX-II, Vit D, CRP	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (age)	[years]	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (level of education)	International Standard Classification of Education (ISCED)	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (type and severity of hemophilia)	Type and severity of hemophilia	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (type and history of substitutional therapy )	Type and history of substitutional therapy	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (history of joint bleedings)	annualized bleeding rate	May 2018 - Oct 2018 (anticipated)
Secondary	Background factors (inhibitors & immune-tolerance therapy)	Inhibitors & immune-tolerance therapy history	May 2018 - Oct 2018 (anticipated)
Secondary	Hemophilia joint health score (HJHS)	Clinical score [dimensionless]	May 2018 - Oct 2018 (anticipated)